Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.93 – $3.50
17% from low
Exchange
OTC Link
OTHER
P/S (TTM)
0.1
EV / FCF (TTM)
45.2
SHANGHAI FOSUN PHARM REG
No one on the platform currently holds SFOSF.
No tracked institution reports a position in SFOSF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-20 | $0.4500 | 2026-08-14 |
| 2025-07-28 | $0.3500 | 2025-08-22 |
| 2024-07-30 | $0.3000 | 2024-08-23 |
No one on the platform has traded SFOSF yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 2.8% | 6.9% | 8.1% | — | — | — |
| Rev. Growth % | -1.6% | 5.9% | ||||
| Profit Margin % | 8.1% | 8.2% | 11.2% | |||
| Free Cash Flow Margin % | 1.9% | -1.8% | -1.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +22.8% on the P/E track.
At today's price, your expected annual return is +25.9% on the P/E track.
At today's price, your expected annual return is +29.1% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $44.8B | +9.3% | $1.50 | $1.44–$1.57 | 1.5× | 1 |
| 2027 | $45.9B | +2.4% | $1.69 | $1.63–$1.77 | 1.3× | 1 |
| 2028 | $48.8B | +6.4% | $1.94 | $1.87–$2.03 | 1.1× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-10-29 | $0.04 | $0.04 | +4.6% |
| 2025-08-26 | $0.04 | $0.09 | +111.3% |
| 2025-03-25 | $0.03 | $0.04 | +23.7% |
| 2024-08-27 | $0.04 | $0.06 | +62.3% |
| 2024-03-26 | $0.04 | $0.03 | -14.6% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| SFOSFShanghai Fosun Pharmaceutical (Group) Co., Ltd. | $2.20 | +0.00% | $5.8B | — |
| BDULFBangkok Dusit Medical Services Public Company Limited | $0.56 | +0.00% | $8.9B | — |
| BDUUFBangkok Dusit Medical Services Public Company Limited | $0.64 | +0.00% | $10.2B | — |
| BIOVFSwedish Orphan Biovitrum AB (publ) | $48.13 | +0.00% | $16.7B | — |
| CSPCYCSPC Pharmaceutical Group Limited |
| $4.49 |
| +2.28% |
| $12.9B |
| — |
| ESAIYEisai Co., Ltd. | $7.79 | +1.83% | $8.8B | — |
| ESALFEisai Co., Ltd. | $30.61 | +0.00% | $8.6B | — |
Source: Financial Modeling Prep · peers by sector/industry